DMAC News and Press, DiaMedica Therapeutics Inc.

“No Objection Letter” from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia program featured in recent National Public Radio (NPR) coverage DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conference...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 share...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Foo...

2025-11-13 10:02:08 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript DiaMedica Therapeutics GAAP EPS of -$0.17 misses by $0.01 Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnin...

2025-11-13 10:01:34 ET DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript

2025-11-12 16:36:43 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics Read the full article on Seeking Alpha ...

Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthca...